Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
1.
J Med Internet Res ; 24(2): e16128, 2022 02 08.
Artículo en Inglés | MEDLINE | ID: mdl-35133288

RESUMEN

BACKGROUND: One in eight women is diagnosed with breast cancer in the course of their life. As systematic palliative treatment has only a limited effect on survival rates, the concept of health-related quality of life (HRQoL) was developed for measurement of patient-centered outcomes. Various studies have already demonstrated the reliability of paper-based patient-reported outcome (pPRO) and electronic patient-reported outcome (ePRO) surveys and that the 2 means of assessment are equally valid. OBJECTIVE: The aim of this study was to analyze the acceptance and evaluation of a tablet-based ePRO app for breast cancer patients and to examine its suitability, effort, and difficulty in the context of HRQoL and sociodemographic factors. METHODS: Overall, 106 women with adjuvant or advanced breast cancer were included in a 2-center study at 2 major university hospitals in Germany. Patients were asked to answer HRQoL and PRO questionnaires both on a tablet on-site using a specific eHealth assessment website and on paper. The suitability, effort, and difficulty of the app and self-reported technical skills were also assessed. Only the results of the electronically acquired data are presented here. The results of the reliability of the pPRO data have already been published elsewhere. RESULTS: Patients regarded the ePRO assessment as more suitable (80/106, 75.5%), less stressful (73/106, 68.9%), and less difficult (69/106, 65.1%) than pPRO. The majority of patients stated that ePRO assessment improves health care in hospitals (87/106, 82.1%). However, evaluation of ePROs depended on the level of education (P=.003) in the dimensions of effort and difficulty (regression analysis). The app was rated highly in all categories. HRQoL data and therapy setting did not show significant correlations with the app's evaluation parameters. CONCLUSIONS: The results indicate that ePRO surveys are feasible for measuring HRQoL in breast cancer patients and that those patients prefer ePRO assessment to pPRO assessment. It can also be seen that patients consider ePRO assessment to improve hospital health care. However, studies with larger numbers of patients are needed to develop apps that address the needs of patients with lower levels of education and technical skills.


Asunto(s)
Neoplasias de la Mama , Aplicaciones Móviles , Neoplasias de la Mama/terapia , Electrónica , Femenino , Humanos , Medición de Resultados Informados por el Paciente , Estudios Prospectivos , Calidad de Vida , Reproducibilidad de los Resultados
2.
BioSC. (Curitiba, Impresso) ; 80(2): 51-53, 20220000.
Artículo en Portugués | LILACS | ID: biblio-1438537

RESUMEN

Introdução: A intolerância à lactose é síndrome decorrente da má digestão do dissacarídeo lactose por deficiência da enzima lactase, gerando sintomas principalmente gastrintestinais. Ela envolve 4 causas principais: deficiência congênita de lactase; deficiência de lactase de desenvolvimento; intolerância primária à lactose; e deficiência secundária à lactase. Objetivo: Revisão da apresentação clínica da intolerância à lactose e os principais métodos disponíveis para seu diagnóstico clínico. Método: Revisão narrativa da base de dados PubMed, por meio das palavras-chave "lactose intolerance" e "genetic test" utilizando o descritor boleano and. Foram incluídos somente artigos em língua inglesa e publicados entre os anos de 2017 e 2022, totalizando 8 artigos. Resultado: O diagnóstico de intolerância à lactose relaciona-se com o seu tipo e utiliza-se dos principais métodos: teste oral de tolerância à lactose, teste genético, teste do hidrogênio expirado. Conclusão: Quanto aos métodos de diagnóstico, o teste do hidrogênio expirado é o de escolha, por não ser invasivo, possuir execução fácil e baixo custo. Entretanto, ele não dispensa associação com outras técnicas diagnósticas. O teste genético também é muito útil e sua vantagem é que não há necessidade da realização do teste oral de tolerância.


Introduction: Lactose intolerance is a syndrome resulting from maldigestion of the disaccharide lactose due to lactase enzyme deficiency causing symptoms mainly gastrointestinal. It involves 4 main causes: congenital lactase deficiency; developmental lactase deficiency; primary lactose intolerance; and secondary lactase deficiency. Objective: Review of the clinical presentation of lactose intolerance and the main methods available for its clinical diagnosis. Methods: Literature review in the PubMed database, using the keywords "lactose intolerance" and "genetic test" and using the Boolean data type and. Only articles in English and published between the years 2017 and 2022 were included, totalizing 8 articles. Results: The diagnosis of lactose intolerance is related to its type and uses the main diagnostic tests: oral lactose tolerance, genetic, expired hydrogen. Conclusion: Regarding diagnostic methods, the expired hydrogen test is the one of choice, as it is not invasive, is easy to perform and has low cost. However, it does not dispense association with other diagnostic techniques. Genetic testing is also very usefull and its advantage is that there is no need to use the oral lactose tolerance test.

3.
JMIR Cancer ; 7(4): e25776, 2021 Oct 12.
Artículo en Inglés | MEDLINE | ID: mdl-34636732

RESUMEN

BACKGROUND: Health-related quality of life (HRQoL) is used to evaluate the treatment of metastatic breast cancer. In a long-term therapy setting, HRQoL can be used as an important benchmark for treatment success. With the help of digital apps, HRQoL monitoring can be extended to more remote areas and be administered on a more frequent basis. OBJECTIVE: This study aims to evaluate 3 common HRQoL questionnaires in metastasized breast cancer in terms of TTD in a digital, web-based setting. We further aim to examine the development of the HRQoL in different systemic treatment groups in each of these evaluation instruments. METHODS: A total of 192 patients with metastatic breast cancer were analyzed in this bicentric prospective online cohort study at two German university hospitals. Patients completed questionnaires on HRQoL (EuroQol Visual Analog Scale [EQ-VAS], EuroQol 5 Dimension 5 Level [EQ-5D-5L], European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 item [EORTC QLQ-C30]) via an online platform over a 6-month period. Treatment schedules and medical history were retrieved from medical records. Unadjusted Cox regression analysis on treatment-related factors was performed. We conducted subgroup analyses in regard to TTD events between different treatments. RESULTS: The EQ-VAS showed a higher rate of deterioration after 8 weeks (84/179, 46.9%) than the EQ-5D-5L (47/163, 28.8%) and EORTC QLQ-C30 (65/176, 36.9%). Unadjusted Cox regression revealed significant connections between known metastases in the liver (P=.03, HR 1.64, 95% CI 1.06-2.52) and pleura (P=.04, HR 0.42, 95% CI 0.18-0.96) in the EQ-VAS. Significant relations between EQ-VAS events and single EQ-5D-5L items and the EQ-5D-5L summary score were demonstrated. All treatment groups significantly differed from the CDK4/6 inhibition subgroup in the EQ-VAS. CONCLUSIONS: Compared to the EQ-5D-5L and QLQ-C30, the EQ-VAS showed a higher rate of deterioration after 8 weeks. Significant connections to certain metastatic locations were only detected in the EQ-VAS. The EQ-VAS is capable of reflecting the distinctive HRQoL profiles of different systemic treatments as well as the different aspects of HRQoL presented in the EQ-5D-5L. TTD with the EQ-VAS is an adequate mean of examining longitudinal development of HRQoL among breast cancer patients.

4.
BMC Womens Health ; 20(1): 135, 2020 06 29.
Artículo en Inglés | MEDLINE | ID: mdl-32600323

RESUMEN

BACKGROUND: The Mayer-Rokitansky-Küster-Hauser syndrome, MRKHS, is a rare (orphan) disease characterized by the aplasia or hypoplasia of the uterus and the vagina. In women's health research, little is known as to how much care provision for patients with MRKHS takes into account their socio-demographic together with their clinical characteristics. This work examines the patients' socio-demographic characteristics, highlighting issues of inappropriate and deficient provision of care. METHODS: The study was carried out as part of the larger TransCareO project and included a group of N=129 MRKHS patients who underwent surgery between 2008 and 2012. Using a specially developed questionnaire, we analyzed MRKHS patients' data found both in the clinical documentation of the Department for Women's Health, University Hospital of Tübingen and the patient surveys of the Center for Rare Genital Malformations (CRGM/ ZSGF). Patients who took part in interviews were compared with non-respondents. RESULTS: Patient respondents and non-respondents did not differ as to the parameters of interest. In most cases, primary amenorrhea was reported as an admission reason. In 24% of patients, a medical intervention (hymenal incision or hormone treatment) already occurred before admission to the Center in Tübingen and proper diagnosis of MRKHS. About one third received in advance inappropriate treatment. During the therapy, more than half of the patients were in a solid partnership. 10% of the family anamneses documented the occurrence of urogenital malformations. CONCLUSIONS: Care provision for MRKHS patients is largely characterized by delayed proper diagnosis and in part, by inappropriate treatment attempts; there are also indications of regional differences. Anamnestic clues such as an asymptomatic amenorrhea or renal abnormalities of unclear origin still fail to result early enough in referral to a center on the basis of suspected MRKHS diagnosis. Urogenital malformations in the family are more common in patients than in the general population. For patients, a wide range of burdens are associated with the diagnosis. Abnormalities compared to their female peers occur, for instance, in the partnership status: MRKHS patients have more rarely a partner.


Asunto(s)
Trastornos del Desarrollo Sexual 46, XX/diagnóstico , Anomalías Congénitas/diagnóstico , Conductos Paramesonéfricos/anomalías , Útero/anomalías , Vagina/anomalías , Adolescente , Adulto , Femenino , Investigación sobre Servicios de Salud , Humanos , Persona de Mediana Edad , Enfermedades Raras , Factores Socioeconómicos , Salud de la Mujer , Adulto Joven
5.
J Med Internet Res ; 21(1): e10004, 2019 01 22.
Artículo en Inglés | MEDLINE | ID: mdl-30668517

RESUMEN

BACKGROUND: The most frequent malignant disease in women is breast cancer. In the metastatic setting, quality of life is the primary therapeutic goal, and systematic treatment has only a limited effect on survival rates; therefore, the concept of the health-related quality of life (HRQoL) and measurement of patient-reported outcomes (PROs) are gaining more and more importance in the therapy setting of diseases such as breast cancer. One of the frequently used questionnaires for measuring the HRQoL in patients with breast cancer is the Functional Assessment of Cancer Therapy-Breast (FACT-B). Currently, paper-based surveys still predominate, as only a few reliable and validated electronic-based questionnaires are available. ePRO tools for the FACT-B questionnaire with proven reliability are missing so far. OBJECTIVE: The aim of this study was to analyze the reliability of tablet-based measurement of FACT-B in the German language in adjuvant (curative) and metastatic breast cancer patients. METHODS: Paper- and tablet-based questionnaires were completed by a total of 106 female adjuvant and metastatic breast cancer patients. All patients were required to complete the electronically based (ePRO) and paper-based version of the FACT-B. A frequency analysis was performed to determine descriptive sociodemographic characteristics. Both dimensions of reliability (parallel forms reliability using Wilcoxon test and test of internal consistency using Spearman ρ) and agreement rates for single items, Kendall tau for each subscale, and total score were analyzed. RESULTS: High correlations were shown for both dimensions of reliability (parallel forms reliability and internal consistency) in the patients' response behavior between paper-based and electronically based questionnaires. Regarding the reliability test of parallel forms, no significant differences were found in 35 of 37 single items, while significant correlations in the test for consistency were found in all 37 single items, in all 5 sum individual item subscale scores, as well as in total FACT-B score. CONCLUSIONS: The ePRO version of the FACT-B questionnaire is reliable for patients with breast cancer in both adjuvant and metastatic settings, showing highly significant correlations with the paper-based version in almost all questions all subscales and the total score.


Asunto(s)
Neoplasias de la Mama/terapia , Medición de Resultados Informados por el Paciente , Psicometría/métodos , Calidad de Vida/psicología , Femenino , Humanos , Reproducibilidad de los Resultados , Encuestas y Cuestionarios
6.
Arch Gynecol Obstet ; 298(2): 363-372, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-29931523

RESUMEN

PURPOSE: Pregnancy-associated breast cancer (PABC) is considered the second most common malignancy affecting pregnancy. The limited knowledge as to long-term survival is nonuniform. This retrospective study aims to contribute by a follow-up of pregnancies of breast cancer patients treated at a single university centre with focus on maternal long-term survival in relation to time point of diagnosis (before, during, and after pregnancy). METHODS: Data of 25 patients were reviewed for the period between 2000 and 2009 in relation to their neonatal and maternal outcome parameters as well as their maternal breast cancer outcomes by assessing maternal mortality at annual intervals up to a maximum of 10 years follow-up. RESULTS: Median age at diagnosis was 33 years. Maternal survival rate of the total collective came to 76% after 5 years and to 68% after 10 years. The newborns were healthy, 22% of them presented with a 1'Apgar score 5-7. Preterm delivery occurred in 53%. PABC significantly affected maternal survival compared to the national breast cancer cohort at 5 years and barely significantly at 10 years, with highly significant (p < 0.003) to significant (p < 0.01) effects at 5 and 10 years, respectively, for PABC diagnosed during and after pregnancy. CONCLUSIONS: The present findings on survival rates suggest that maternal medical assessment at the beginning of and during further course of pregnancy should include a scrutinized thorough breast examination. Conveying/delivering special competences to monitor these high-risk pregnancies at the interface of oncological care should be considered an obligatory part of academic medical education, obstetrical training and interprofessional midwifery education.


Asunto(s)
Neoplasias de la Mama/mortalidad , Complicaciones Neoplásicas del Embarazo/mortalidad , Adulto , Puntaje de Apgar , Peso al Nacer , Neoplasias de la Mama/complicaciones , Neoplasias de la Mama/patología , Femenino , Humanos , Recién Nacido , Estudios Longitudinales , Embarazo , Complicaciones Neoplásicas del Embarazo/patología , Resultado del Embarazo , Estudios Retrospectivos , Tasa de Supervivencia , Resultado del Tratamiento
7.
J Med Internet Res ; 19(9): e322, 2017 09 14.
Artículo en Inglés | MEDLINE | ID: mdl-28912116

RESUMEN

BACKGROUND: Breast cancer represents the most common malignant disease in women worldwide. As currently systematic palliative treatment only has a limited effect on survival rates, the concept of health-related quality of life (HRQoL) is gaining more and more importance in the therapy setting of metastatic breast cancer. One of the major patient-reported outcomes (PROs) for measuring HRQoL in patients with breast cancer is provided by the European Organization for Research and Treatment of Cancer (EORTC). Currently, paper-based surveys still predominate, as only a few reliable and validated electronic-based questionnaires are available. Facing the possibilities associated with evolving digitalization in medicine, validation of electronic versions of well-established PRO is essential in order to contribute to comprehensive and holistic oncological care and to ensure high quality in cancer research. OBJECTIVE: The aim of this study was to analyze the reliability of a tablet-based measuring application for EORTC QLQ-C30 in German language in patients with adjuvant and (curative) metastatic breast cancer. METHODS: Paper- and tablet-based questionnaires were completed by a total of 106 female patients with adjuvant and metastatic breast cancer recruited as part of the e-PROCOM study. All patients were required to complete the electronic- (e-PRO) and paper-based versions of the HRQoL EORTC QLQ-C30 questionnaire. A frequency analysis was performed to determine descriptive sociodemographic characteristics. Both dimensions of reliability (parallel forms reliability [Wilcoxon test] and test of internal consistency [Spearman rho and agreement rates for single items, Pearson correlation and Kendall tau for each scale]) were analyzed. RESULTS: High correlations were shown for both dimensions of reliability (parallel forms reliability and internal consistency) in the patient's response behavior between paper- and electronic-based questionnaires. Regarding the test of parallel forms reliability, no significant differences were found in 27 of 30 single items and in 14 of 15 scales, whereas a statistically significant correlation in the test of consistency was found in all 30 single items and all 15 scales. CONCLUSIONS: The evaluated e-PRO version of the EORTC QLQ-C30 is reliable for patients with both adjuvant and metastatic breast cancer, showing a high correlation in almost all questions (and in many scales). Thus, we conclude that the validated paper-based PRO assessment and the e-PRO tool are equally valid. However, the reliability should also be analyzed in other prospective trials to ensure that usability is reliable in all patient groups. TRIAL REGISTRATION: ClinicalTrials.gov NCT03132506; https://clinicaltrials.gov/ct2/show/NCT03132506 (Archived by WebCite at http://www.webcitation.org/6tRcgQuou).


Asunto(s)
Neoplasias de la Mama/epidemiología , Calidad de Vida/psicología , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/psicología , Femenino , Humanos , Persona de Mediana Edad , Estudios Prospectivos , Reproducibilidad de los Resultados , Encuestas y Cuestionarios
8.
JMIR Cancer ; 3(2): e11, 2017 Aug 07.
Artículo en Inglés | MEDLINE | ID: mdl-28784595

RESUMEN

BACKGROUND: Patient-reported outcomes (PROs) play an increasingly important role as an adjunct to clinical outcome parameters in measuring health-related quality of life (HRQoL). In fact, PROs are already the accepted gold standard for collecting data about patients' subjective perception of their own state of health. Currently, paper-based surveys of PRO still predominate; however, knowledge regarding the feasibility of and barriers to electronic-based PRO (ePRO) acceptance remains limited. OBJECTIVE: The objective of this trial was to analyze the willingness, specific needs, and barriers of adjuvant breast cancer (aBC) and metastatic breast cancer (mBC) patients in nonexposed (no exposure to electronic assessment) and exposed (after exposure to electronic assessment decision, whether a tablet-based questionnaire is favored) settings before implementing digital ePRO assessment in relation to health status. We also investigated whether providing support can increase the patients' willingness to participate in such programs. METHODS: The nonexposed patients only answered a paper-based questionnaire, whereas the exposed patients filled out both paper- and tablet-based questionnaires. The assessment comprised socioeconomic variables, HRQoL, preexisting technical skills, general attitude toward electronic-based surveys, and potential barriers in relation to health status. Furthermore, nonexposed patients were asked about the existing need for technological support structures. In the course of data evaluation, we performed a frequency analysis as well as chi-square tests and Wilcoxon signed-rank tests. Subsequently, relative risks analysis, univariate categorical regression (CATREG), and mediation analyses (Hayes' bias-corrected bootstrap) were performed. RESULTS: A total of 202 female breast cancer patients completed the PRO assessment (nonexposed group: n=96 patients; exposed group: n=106 patients). Self-reported technical skills were higher in exposed patients (2.79 vs 2.33, P ≤.001). Significant differences were found in relation to willingness to use ePRO (92.3% in the exposed group vs 59% in the nonexposed group; P=.001). Multiple barriers were identified, and most of them showed statistically significant differences in favor of the exposed patients (ie, data security [13% in the exposed patients vs 30% in the nonexposed patients; P=.003] and no prior technology usage [5% in the exposed group vs 15% in the nonexposed group; P=.02]), whereas the differences in disease burden (somatic dimension: 4% in the exposed group vs 9% in the nonexposed group; P=.13) showed no significance. In nonexposed patients, requests for support services were identified, which could increase their ePRO willingness. CONCLUSIONS: Significant barriers in relation to HRQoL, cancer-related restrictions, and especially the setting of the survey were identified in this trial. Thus, it is necessary to address and eliminate these barriers to ensure data accuracy and reliability for future ePRO assessments. Exposure seems to be a potential option to increase willingness to use ePRO and to reduce barriers.

9.
Rev. méd. Paraná ; 73(2): 60-63, 2015.
Artículo en Portugués | LILACS-Express | LILACS | ID: biblio-1366182

RESUMEN

Descrevemos um caso clínico de uma paciente lúpica com anemia refratária devido à infecção por Citomegalovírus (CMV) que obteve boa resposta ao tratamento com ganciclovir. Discutimos as diferentes etiologias de anemia em um paciente com Lúpus Eritamatoso Sistêmico (LES) e sua importância para o adequado tratamento do paciente. Descritores: Anemia; citomegalovírus (CMV); Lupus eritematosos sistêmico (LES)Cytomegalovirus anemia in a systemic lúpus erythematosus patient.


We describe a case of a lupus patient with a refractory anemia due to cytomegalovirus (CMV) infection with good response to treatment with ganciclovir. We also discuss the different etiologies of anemia in a patient with Systemic Lupus Erythematosus (SLE) and its importance for the proper treatment of the patient. Key words: Anemia, Systemic Lupus Erythematosus (SLE), cytomegalovirus (CMV).

10.
Rev. méd. Paraná ; 73(2): 67-70, 2015.
Artículo en Portugués | LILACS-Express | LILACS | ID: biblio-1366185

RESUMEN

A falência hepática fulminante (FHF) é uma doença rara com tendência a um desfecho trágico. As hepatites virais são uma causa incomum e ainda há controvérsias se o vírus da hepatite C (HCV) poderia ser um fator etiológico. Relatamos o caso de uma paciente feminina de 50 anos, hipertensa, diabética, lúpica e com deficiência de fator V de Leiden, que foi a óbito por FHF por hepatite aguda por HCV comprovada por sorologias e PCR-quantitativo. Outros casos de FHF por HCV em pacientes com comorbidades hepáticas ou imuno-mediadas serão revisados, bem como evidências imunogenéticas que levaram a interpretação da FHF como tendo um fundo auto-imune que ainda precisa ser mais estudado.


Fulminant Hepatic Failure (FHF) is a rare condition that tends to have a tragical disclosure. Viral hepatitis are an uncommon cause and it is still controversial if hepatitis C virus (HCV) could be an etiological factor. We report the case of a 50-year-old female patient who was diabetic, hipertense, lupic and had Leiden´s factor V deficiency, who died of FHF caused by acute hepatitis C proven by serology and quantitative-PCR. Other cases of FHF caused by HCV in patients with hepatic comorbidities or imunne-mediated diseases will be reviewed, as well as immunogenetic evidences that can lead to interpretation of FHF a shaving an auto-immune background that still needs more studying.

11.
Rev. méd. Paraná ; 73(2): 9-12, 2015.
Artículo en Portugués | LILACS-Express | LILACS | ID: biblio-1363455

RESUMEN

Objetivos: Verificar a prevalência de FAN positivo em portadores de AR e estudar a sua correlação com elementos clínicos. Material e Métodos: Foram estudados 113 pacientes portadores de AR quanto à idade do diagnóstico, sexo, presença de nódulos reumatóides, presença de alterações radiológicas (osteoporose justa articular e erosões) em RX de mãos, presença de fator reumatoide. Estes dados foram correlacionados com a presença do FAN. Resultados: A prevalência de FAN positivo foi de 21,24%, sem diferença estatisticamente significativa entre os sexos (p=0,553). Os títulos variaram entre 1:40 e 1:320, sendo a maioria (83,3%) padrão pontilhado. Não houve significância estatística entre o FAN positivo e idade de início da doença (p=0,4611) ou presença de alterações radiológicas (p=0,4397). Houve correlação significante entre FAN positivo e presença de nódulos reumatoides, onde 50% dos pacientes com nódulos tinham este anticorpo(p=0,0197). Conclusão: O presente estudo concluiu que os pacientes com AR nodular possuíam mais FAN positivo, o que pode ser indicativo de associação deste anticorpo com doença mais grave.


Objective: To verify the prevalence of ANA in patients with RA and study its correlation with clinical findings. Material and Methods: We studied 113 patients with rheumatoid arthritis for diagnosis age, sex, rheumatoid nodules, radiologic findings in hand X-rays and rheumatoid factor. These results were correlated with the presence of ANA. Results: About 21.24% of the patients had positive ANA and no significant gender differenceswere observed. The titers were between 1:40 to 1:320 and most of them (83.3%) with mottled pattern. No statistical significance could be found among ANA positive patients with regards to age of diagnosis (p=0.46) or radiological findings (p=0.43). There was a positive correlation of presence of rheumatoid nodules and finding of positive ANA (p=0.01). Conclusion: We conclude that patients with nodular RA have more frequently positive ANA, which can indicate that this antibody is present in more severe disease.

12.
Rev. méd. Paraná ; 73(2): 38-41, 2015.
Artículo en Portugués | LILACS-Express | LILACS | ID: biblio-1363644

RESUMEN

Objetivo: Verificar a prevalência de efeitos colaterais em usuários de metotrexate (MTX) para artrite reumatoide e lúpus. Material e métodos: Foram revisados os prontuários de 49 usuários de MTX para alterações de provas de função hepática, ocorrência de citopenias e de pneumonites inersticiais. Foram coletados dados como tempo de uso, dose semanal de metotrexate, doença de base e que indicou a medicação e associação com outros modificadores de doença Resultado: Cerca de 12% dos pacientes desenvolveram efeitos colaterais requerendo a retirada da droga. O efeito colateral mais comum foi alteração de transaminases. Estas alterações não dependeram de dose semanal usada (p=0,54 para SGOT e p=0,95 para SGPT), nem do tempo de uso (SGOT com p=0,59 e SGPT com p=0,40), mas foram mais comum em usuários de associação com sulfassalazina (p=0,0029). Pneumonite intersticial foi vista em 4,08% dos casos sendo todos os pacientes com esta complicação portadores de artrite reumatóide. Citopenia apareceu em somente 1 paciente. Conclusão: O uso de MTX demonstrou ser seguro em pacientes com doenças reumáticas.


Objective: To verify the prevalence of collateral side effects in rheumatoid arthritis and lupus MTX treated patients. Material and methods: We reviewed 49 charts of MTX users for hepatic dysfunction, cytopenias and interstitial pneumonitis occurrence. Data from treatment duration, weekly used doses, associations with other disease modifying agents and disease that indicated the treatment were also collected. Results: In was found that there were side effects that precluded further drug use in 12% of patients. The commonest was raised transaminases. This side effect wasn't associated with weekly MTX dose (p=0.54 for SGOT and p=0.95 for SGPT), neither with treatment time (SGOT with p=0.59 and SGPT with p=0.40). A relationship of raised transaminases and use of associated sulfassalazine was found (p=0.0029). Interstitial pneumonitis was seen in 4.08% of patients being all of them rheumatoid arthritis patients. Cytopenia appeared in just one patient. Conclusion: The MTX use was found to be safe in rheumatic diseases patients.

13.
Rev. méd. Paraná ; 73(2): 46-50, 2015.
Artículo en Portugués | LILACS-Express | LILACS | ID: biblio-1364041

RESUMEN

Objetivo: Avaliar a prevalência de tais doenças em pacientes com tireoidite de Hashimoto (TH). Métodos: Foi utilizada uma amostra aleatória de 155 pacientes com TH, questionando-se idade, tempo de diagnóstico, existência de autoanticorpos tireoidianos e coexistência de outras doenças. Resultados: A amostra compunha-se de 135 mulheres e 20 homens, com idade média de 53 anos e duração média de doença de 6 anos. Existia positividade para anticorpo antitireoperoxidase (TPO) e 54,54% para antitireoglobulina (TG). Em 67,82% existia positividade para algum dos anticorpos antitireoidianos. Em 6,45% dos pacientes havia uma segunda doença associada, destes, em 40% artrite reumatóide, em 20% lúpus eritematoso sistêmico, em 10% polimiosite, em10% psoríase e em 10% retocolite ulcerativa. Uma paciente com AR tinha também esclerodermia associada. Conclusão: Concluiu-se que em TH existia uma prevalência de 6% de uma segunda doença de autoimunidade, o que é compatível com a literatura. Como o hipotireoidismo pode simular doenças reumáticas, esse conhecimento é importante no manejo correto destes pacientes.


Objective: It is to assess the prevalence of such diseases in patients with Hashimoto's thyroiditis (HT). Methods: We used a random sample of 155 patients with HT, questioning whether age, time of diagnosis, presence of thyroid autoantibodies and the coexistence of other diseases. Results: The sample consisted of 135 women and 20 men, with mean age was 53 years and with mean disease duration of 6 years. Eighty six percent were positive for anti-thyroperoxidase (TPO) and 54.54% for thyroglobulin (TG). In 67.82% existed at least one antithyroid antibody. In 6.45% of patients there was a second disease associated; 40% were reumatoid arthritis, 20% systemic lupus erythematosus, 10% polymyositis, 10% psoriasis and 10% of ulcerative colitis. One patient with RA had also 50 Prevalência de Doenças de Autoimunidade em Pacientes com Tireoidite de Hashimoto. scleroderma. Conclusion: We conclude that in TH there was a prevalence of 6% of a second autoimmune disease, which is according with the literature. Because hypothyroidism can mimic rheumatic diseases, such knowledge is important in the correct management of these patients.

14.
Rev. méd. Paraná ; 73(2): 78-80, 2015.
Artículo en Portugués | LILACS-Express | LILACS | ID: biblio-1366474

RESUMEN

O lúpus eritematosos sistêmico (LES) é uma doença autoimune, inflamatória e crônica com manifestações sistêmicas. A glomerulonefrite é conhecida como uma das complicações mais comuns do LES. As manifestações renais são difíceis de caracterizar e a nefrite lúpica é um preditor importante do prognóstico. O fator antinuclear (FAN) geralmente é detectado em 95% dos pacientes com LES. Em casos de FAN negativo, a biópsia renal, é necessária porque, além de estabelecer a classificação histológica, tem implicações prognósticas e terapêuticas e exclui outras possibilidades diagnósticas. No presente trabalho é apresentado um caso de uma paciente feminina, 30 anos, com glomerulonefrite FAN negativa após uma gravidez complicada por doença hipertensiva associada à gravidez, sendo diagnosticada com LES por ter biópsia renal característica.


Systemic lupus erythematous (SLE) is an autoimmune disease, and inflammatory disorder with systemic characteristics. Glomerulonephritis is known as one of the most common complications of SLE. The renal manifestations are difficult to characterize and lupus nephritis is an important predictor of prognosis. The antinuclear antibodies (ANA) are usually detected in 95% of patients with SLE. In cases of ANA negative, renal biopsy is necessary because, in addition to establishing the histological classification, has prognostic and therapeutic implications and exclude other diagnostic possibilities. In this paper we present a case of a 30 years old female, with an ANA negative glomerulonephritis after a Specific Hypertensive Disease of Pregnancy that was diagnosed as lupus because of a characteristic renal biopsy.

15.
Rev. méd. Paraná ; 73(2): 95-96, 2015.
Artículo en Portugués | LILACS-Express | LILACS | ID: biblio-1366619

RESUMEN

Descreve-se aqui o caso de um paciente de 55 anos que desenvolveu poliartrite de pequenas articulações com características muito semelhantes as da artrite reumatoide e que desapareceu com tratamento de tuberculose pulmonar. Atribuindo o caso a uma forma de reumatismo tuberculoso como o descrito por Poncet em 1897, os autores trazem à tona este diagnóstico, o qual deve ser lembrado uma vez que tuberculose tem se tornado, novamente, uma infecção frequente.


We described the case of a 55 year old patient who developed small joint polyarthritis with characteristics very similar to those of rheumatoid arthritis that disappeared with treatment of pulmonary tuberculosis. Assigning the case to a form of rheumatism secondary to tuberculosis as described by Poncet 1897, the authors bring out this diagnosis, which must be remembered that once tuberculosis has become, again, a common infection.

16.
GED gastroenterol. endosc. dig ; 21(2): 82-84, mar.-abr. 2002.
Artículo en Portugués | LILACS | ID: lil-316481

RESUMEN

Os antiinflamatórios não hormonais podem ser causa de lesão hepática, sendo esta determinada muito mais por mecanismo idiossincrático do que por efeito tóxico direto. O espectro clínico dessa lesão varia desde elevações assintomáticas das aminotransferases até quadros de hepatite aguda grave com ictericia hepatocelular, evoluindo para obito. A populacção particularmente vulnerável a essa complicação engloba pacientes do sexo feminino, idosas, portadoras de osteoartrites. Descreve-se um caso de hepatotoxicidade grave por diclofenaco, um dos antiinflamátorios mais utilizados em nosso meio


Asunto(s)
Femenino , Anciano , Antiinflamatorios , Diclofenaco , Hipersensibilidad a las Drogas , Hepatitis , Antiinflamatorios
17.
Rev. Soc. Bras. Med. Trop ; 29(1): 21-5, Jan.-Feb. 1996. ilus, tab
Artículo en Inglés | LILACS | ID: lil-187169

RESUMEN

We performed a clinico-pathological study of 163 untreated cases of chronic hepatitis C. Eighty five percent of the patients were clinically asymptomatic and their physical examinations showed unremarkable or minimal changes at the time of the liver biopsy. Liver function tests tended to present slight abnormalities, involving mild elevations of the activity of the aminotransferases and gamma-glutamil transferase levels. In spite of these mild abnormalities, advanced chronic liver disease was histologically detected in eighty nine percent of the patients, mainly showing chronic active hepatitis. The most characteristic histological finding was an interlobular bile duct damage, which correlated with the presence of lymphoid aggregates in the portal tracts and with the development of fibrosis.


Asunto(s)
Humanos , Femenino , Adulto , Anciano , Masculino , Hepatitis C/patología , Hepatitis Crónica/patología , Antígenos de Superficie de la Hepatitis B/sangre , Biopsia , Cirrosis Hepática/diagnóstico , Cirrosis Hepática/patología , Pruebas Enzimáticas Clínicas , Hígado/patología , Anticuerpos contra la Hepatitis C/sangre , Hepatitis C/diagnóstico , Hepatitis Crónica/diagnóstico , Persona de Mediana Edad , Transaminasas/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA